CoChat

Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.

Abstract

The gut microbiome can influence the development of tumours and the efficacy of cancer therapeutics 1-5 ; however, the multi-omics characteristics of antitumour bacterial strains have not been fully elucidated. In this study, we integrated metagenomics, genomics and transcriptomics of bacteria, and analyses of mouse intestinal transcriptome and serum metabolome data to reveal an additional mechanism by which bacteria determine the efficacy of cancer therapeutics. In gut microbiome analyses of 96 samples from patients with non-small-cell lung cancer, Bifidobacterium bifidum was abundant in patients responsive to therapy. However, when we treated syngeneic mouse tumours with commercial strains of B. bifidum to establish relevance for potential therapeutic uses, only specific B. bifidum strains reduced tumour burden synergistically with PD-1 blockade or oxaliplatin treatment by eliciting an antitumour host immune response. In mice, these strains induced tuning of the immunological background by potentiating the production of interferon-γ, probably through the enhanced biosynthesis of immune-stimulating molecules and metabolites.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41564-020-00831-6

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 61 references

Cited by

See all 347

Metadata

Authors
Lee, S.-H., Cho, S.-Y., Yoon, Y., Park, C., Sohn, J., Jeong, J.-J., Jeon, B.-N., Jang, M., An, C., Lee, S., Kim, Y. Y., Kim, G., Kim, S., Kim, Y., Lee, G. B., Lee, E. J., Kim, S. G., Kim, H. S., Kim, Y., Kim, H., Yang, H.-S., Kim, S., Kim, S., Chung, H., Moon, M. H., Nam, M. H., Kwon, J. Y., Won, S., Park, J.-S., Weinstock, G. M., Lee, C., Yoon, K. W., & Park, H.
Affiliations
  • Samsung Medical Center (KR)
  • Seoul National University (KR)
  • Gwangju Institute of Science and Technology (KR)
  • Genome and Company (South Korea) (KR)
  • Hoseo University (KR)
  • Yonsei University (KR)
  • Korea Basic Science Institute (KR)
  • The Jackson Laboratory for Genomic Medicine (US)
  • Daegu-Gyeongbuk Medical Innovation Foundation (KR)
  • Ewha Womans University (KR)
Corresponding author
  • Yoon, Kyoung Wan
  • Park, Hansoo
Venue
Nature Microbiology
Published
2021-01-11
Volume
6
Issue
3
Pages
277-288
ISSN
2058-5276 (ISSN-L)
OpenAlex
W3119409060
Cited by
325
References
61
Citations by year
2026: 51 · 2025: 78 · 2024: 65 · 2023: 55 · 2022: 57 · 2021: 19
FWCI
15.68
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Nature Microbiology (publishedVersion)
  • PubMed (publishedVersion)
  • The Mouseion at the JAXlibrary (Jackson Laboratory) (submittedVersion)
  • Seoul National University Open Repository (Seoul National University) (submittedVersion)
Funders
  • Ministry of Trade, Industry and Energy (10067758)
  • National Research Foundation of Korea (NRF-2018M3A9F3056902, 2018R1C1B6005768, NRF-2018R1A2A1A05019794, 2015K1A4A3047851, 2017R1C1B2011196, NRF-2017M3A9F304636)
  • Ewha Womans University (2017-2019)
  • Xi'an Jiaotong University
  • Ministry of Health and Welfare (HI17C1076)
  • National Cancer Center (NCC-1911267)
  • Gwangju Institute of Science and Technology (GIST Research Institute (GRI))
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
Keywords
Bifidobacterium bifidum, gut microbiota, immune checkpoint inhibitors, anti-PD-1 therapy, oxaliplatin, non-small cell lung cancer, strain-level diversity, interferon-gamma, antitumor immunity, bacterial metabolites, cancer immunotherapy response, syngeneic mouse model
MeSH terms
Gastrointestinal Microbiome, Bifidobacterium bifidum, Immune Checkpoint Inhibitors, Animals, Carcinoma, Non-Small-Cell Lung, Drug Therapy, Combination, Humans, Interferon-gamma, Lung Neoplasms, Neoplasms, Experimental, Species Specificity, Tryptophan, Probiotics, Tumor Burden, Mice, Metabolome, Transcriptome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice. https://app.cochat.ai/papers/10.1038/s41564-020-00831-6
The paper
Lee, S.-H., Cho, S.-Y., Yoon, Y., Park, C., Sohn, J., Jeong, J.-J., Jeon, B.-N., Jang, M., An, C., Lee, S., Kim, Y. Y., Kim, G., Kim, S., Kim, Y., Lee, G. B., Lee, E. J., Kim, S. G., Kim, H. S., Kim, Y., . . . Park, H. (2021). Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice. Nature Microbiology. https://doi.org/10.1038/s41564-020-00831-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.